PT-141 (Bremelanotide)
Neutral, BioHarmony verdict
BioHarmony score 5.4 out of 10
PT-141 (bremelanotide) is the only FDA-approved drug for low sexual desire in premenopausal women (Vyleesi, 2019). Its Phase 3 effect on desire was statistically real but below the clinically meaningful threshold, with no significant rise in satisfying sexual events, per Spielmans 2021.
Read full reportWhat is PT-141 (Bremelanotide)?
PT-141, generic name bremelanotide, is a peptide that raises sexual desire from the brain rather than the bloodstream, and it's the only drug the FDA has approved for that purpose in premenopausal women. It activates melanocortin-4 receptors in the hypothalamus, which lifts dopamine signaling in the brain's reward and sexual-motivation circuits, per Pfaus 2022. That central mechanism is the whole point: it can help when the problem is wanting sex, not the physical ability to have it.
From the BioHarmony report, reviewed Sep 8, 2026.
Saved on this device only.
Safety watch-outs
- Severe headache, chest pain, or a home blood-pressure reading at or above 180/110: stop and seek care.
- New or darkening moles, or pigment changes on the face, gums, or breasts: stop and see a dermatologist.
- Persistent low mood, blunted pleasure, or loss of motivation after dosing: stop
- the melanocortin-4 pathway is linked to anhedonia.
- Known cardiovascular disease or uncontrolled high blood pressure: do not use.
Full risk profile in the BioHarmony report.
Dosing as published
Source-reported figures only. This page does not calculate a personal dose.
Working with a vial? The reconstitution calculator covers mixing math, not dosing advice.
More reported protocols
MembersMembers can compare additional reported doses, schedules, and preparation notes.
Educator coverage (3)
Attributed viewpoints, separate from primary research.
- International Peptide Society 2018 Compound Curriculum Dr. William Seeds,
- PT-141 How To Use It For The First Time And Beyond Hunter Williams,
- Bremelanotide: Recommended PT-141 Dosage for Results Jay Campbell,
Trust & sourcing
- Last revieweddone
- Next reviewupcoming
FDA-approved bremelanotide is marketed as Vyleesi for acquired, generalized hypoactive sexual desire disorder in premenopausal women; that approval does not establish other promoted uses.
Primary sources
- Vyleesi (bremelanotide) prescribing information U.S. Food and Drug Administration,
Related peptides for gh axis & hormones
- 6.8Gonadorelin (GnRH)Gonadorelin is synthetic GnRH, a decapeptide that tells the pituitary to release LH and FSH.
- 6.5Kisspeptin-10Kisspeptin-10 is an investigational reproductive neuropeptide that activates the HPG axis through the KISS1R receptor.
- 6.6TB-500 (Thymosin Beta-4 Fragment)TB-500 is a synthetic LKKTETQ fragment marketed for soft-tissue repair, but most human evidence is on full-length topical thymosin beta-4: Sosne 2023 reported corneal…
- 6.2IpamorelinIpamorelin is a selective growth-hormone secretagogue with strong receptor selectivity but almost no human efficacy data: its only completed human efficacy trial…
The Ultimate Peptides Guide
Spot stronger candidates, weak evidence, and seller red flags before you buy.